Endothelial haemostatic markers in members of families with familial combined hyperlipidemia

Thrombosis Research

Volumn 123, Issue 3, 2009, Pages 466-475

  Karásek, David ^a   Vaverková, Helena ^a   Halenka, Milan ^a   Slavík, Luděk ^a   Novotný, Dalibor ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Familial combined hyperlipidemia; Intima media thickness; Plasminogen activator inhibitor 1; Soluble thrombomodulin; Tissue plasminogen activator; von Willebrand factor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COMMON CAROTID ARTERY; CONTROLLED STUDY; FAMILIAL COMBINED HYPERLIPEMIA; FAMILIAL HYPERLIPEMIA; FEMALE; HEMOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; VASCULAR PATENCY;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; FEMALE; HEMOSTASIS; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUNICA INTIMA; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 57849128020     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.02.011     Document Type: Article

References (54)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., and Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a now inherited disorder, combined hyperlipidemia. J Clin Invest 52 (1973) 1544-1568
2. Vaverková H., Weinbergová O., Horčička V., Kubašta M., and Vrublovký P. Familial combined hyperlipidemia. Part II. Clinical picture. Acta Univ Palacki 114 (1986) 243-259
3. Venkatesan S., Cullen P., Pacy P., Halliday D., and Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 13 (1993) 110-118
4. Hokanson J.E., Austin M.A., Zambon A., and Brunzell J.D. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arteriocler Thromb 13 (1993) 427-434
5. Hokanson J.E., Krauss R.M., Albers J.J., Austin M.A., and Brunzell J.D. LDL physical and chemical properties in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 15 (1995) 452-459
6. de Graaf J., and Stalenhoef A.F. Defects of lipoprotein metabolism in familial combined hyperlipidemia. Curr Opin Lipidol 9 (1998) 189-196
7. Keulen E.T., Voors-Pette C., and de Bruin T.W. Familial dyslipidemic hypertension syndrome: Familial combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens 14 (2001) 357-363
8. Celermajer D.S. Endothelial dysfunction: Does it matter? Is it reversible?. J Am Coll Cardiol 30 (1997) 325-333
9. Blann A. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 50 (1993) 125-134
10. Blann A., and Seigneur M. Endothelial cell markers in peripheral arterial disease and vascular surgery. Crit Ischaem 6 (1996) 87-95
11. Kwaan H.C. The biologic role of components of the plasminogen-plasmin system. Prog Cardiovasc Dis 34 (1992) 309-316
12. Blann A. Assessment of endothelial dysfunction: Focus on atherothrombotic disease. Pathofisiol Haemost Thromb 33 (2003) 256-261
13. Schumacher A., Seljeflot I., Sommervoll L., Christensen B., Otterstad J.E., and Arnesen H. Increased levels of endothelial haemostatic markers in patients with coronary heart disease. Thromb Res 105 (2002) 25-31
14. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
15. Morange P.E., Simon C., Alessi M.C., Luc G., Arveiler D., Ferrieres J., et al. PRIME study group. Endothelial cell markers and the risk of coronary heart disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109 (2004) 1343-1348
16. Mannucci P.M., Bernardinelli L., Foco L., Galli M., Ribichini F., Tubaro M., et al. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J Thromb Haemost 3 (2005) 280-286
17. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., and deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20 (2000) 2019-2023
18. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., and Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96 (1997) 1102-1108
19. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., and van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332 (1995) 635-641
20. Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40 (2005) 1215-1220
21. Karasek D., Vaverkova H., Halenka M., Budikova M., and Novotny D. Brachial endothelial function in subjects with familial combined hyperlipidemia and its relationships to carotid artery intima-media thickness. Int Angiol 25 (2006) 418-426
22. Cifkova R., Skodova Z., Poledne R., Adamkova V., Novozamska E., Jozifova M., et al. [Longitudinal trends of total and HDL-cholesterol in a representative population ample of Czech republic]. Vnitr Lek 9 (2000) 501-505
23. Demacker P.N., Veerkamp M.J., Bredie S.J., Marcovina S.M., de Graaf J., and Stalenhoef A.F. Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis 153 (2000) 483-490
24. Veerkamp M.J., de Graaf J., Bredie S.J., Hendriks J.C., Demacker P.N., and Stalenhoef A.F. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 22 (2002) 274-282
25. Dobiasova M., and Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34 (2001) 583-588
26. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
27. Nordehem A., and Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest 58 (1998) 475-483
28. Chandler W.L., Trimble C.L., Loo S.C., and Mornin D. Effect of PAI-1 levels on molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 76 (1990) 930-937
29. Georgieva A.M., Cate H.T., Keulen E.T., van Oerle R., Govers-Riemslag J.W., Hamulyak K., et al. Prothrombotic markers in familial combined hyperlipidemia: evidence of endothelial cell activation and relation to metabolic syndrome. Atherosclerosis 175 (2004) 345-351
30. Paramo J.A., Beloqui O., Colina I., Diez J., and Orbe J. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J Thromb Haemost 3 (2005) 662-664
31. Stroes E., de Bruin T., de Valk H., Erkelens W., Banga J.D., van Rijn H., et al. NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants. Cardiovasc Res 36 (1997) 445-452
32. Pitkanen O.P., Nuutila P., Raitakari O.T., Porkka K., Iida H., Nuotio I., et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 99 (1999) 1678-1684
33. De Michele M., Iannuzzi A., Salvato A., Pauciullo P., Gentile M., Iannuzzo G., et al. Impaired endothelium-dependent vascular reactivity in patients with familial combined hyperlipidaemia. Heart 93 (2007) 78-81
34. Arikan E., and Sen S. Endothelial damage and hemostatic markers in patients with uncomplicated mild-to-moderate hypertension and relationship with risk factors. Clin Appl Thromb Hemost 11 (2005) 147-159
35. Poli K.A., Tofler G.H., Larson M.G., Evans J.C., Sutherland P.A., Lipinska I., et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 101 (2000) 264-269
36. von Kanel R., Hong S., Pung M.A., and Mills P.J. Association of Blood Pressure and Fitness With Levels of Atherosclerotic Risk Markers Pre-Exercise and Post-exercise. Am J Hypertens 20 (2007) 670-675
37. Felmeden D.C., Spencer C.G., Belgore F.M., Blann A.D., Beevers D.G., and Lip G.Y. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16 (2003) 11-20
38. Mertens I., Van der Planken M., Corthouts B., Wauters M., Peiffer F., De Leeuw I., et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 33 (2001) 602-607
39. Mertens I., Van der Planken M., Corthouts B., and Van Gaal L.F. Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?. Metabolism 55 (2006 May) 650-655
40. Rosito G.A., D'Agostino R.B., Massaro J., Lipinska I., Mittleman M.A., Sutherland P., et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 91 (2004) 683-689
41. Gómez-Ambrosi J., Salvador J., Silva C., Pastor C., Rotellar F., Gil M.J., et al. Increased cardiovascular risk markers in obesity are associated with body adiposity: role of leptin. Thromb Haemost 95 (2006) 991-996
42. Natali A., Toschi E., Baldeweg S., Ciociaro D., Favilla S., Sacca L., et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 55 (2006) 1133-1140
43. Foss C.H., Vestbo E., Froland A., Ingerslev J., Gjessing H.J., Mogensen C.E., et al. Insulin resistance is accompanied by increased von Willebrand factor levels in nondiabetic women: a study of offspring of type 2 diabetic subjects compared to offspring of nondiabetic subjects. J Intern Med 252 (2002) 155-163
44. Wannamethee S.G., Lowe G.D., Shaper A.G., Rumley A., Lennon L., and Whincup P.H. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 181 (2005) 101-108
45. Mertens I., Ballaux D., Funahashi T., Matsuzawa Y., Van der Planken M., Verrijken A., et al. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. Thromb Haemost (Dec. 2005) 1190-1195
46. Meigs J.B., O'donnell C.J., Tofler G.H., Benjamin E.J., Fox C.S., Lipinska I., et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55 (2006 Feb) 530-537
47. Pihlajamaki J., Karjalainen L., Karhapaa P., Vauhkonen I., and Laakso M. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol 20 (2000) 164-170
48. Ostergard T., Nyholm B., Hansen T.K., Rasmussen L.M., Ingerslev J., Sorensen K.E., et al. Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training. Metabolism 55 (2006) 1508-1515
49. Balletshofer B.M., Rittig K., Enderle M.D., Volk A., Maerker E., Jacob S., et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101 (2000) 1780-1784
50. Blann A.D., Seigneur M., Steiner M., Boisseau M.R., and McCollum C.N. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 27 (1997) 916-921
51. Blann A.D., Amiral J., and McCollum C.N. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 59 (1997) 115-120
52. Nasser M., Wolosker N., Uint L., Rosoky R.A., Lobato M., Wajngarten M., et al. Relationship between soluble thrombomodulin in patients with intermittent claudication and critical ischemia. Thromb Res 117 (2006) 271-277
53. Salomaa V., Matei C., Aleksic N., Sansores-Garcia L., Folsom A.R., Juneja H., et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353 (1999) 1729-1734
54. Wu K.K. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol 14 (2003) 373-375